Mr Robert Habib
MiNA Therapeutics is a virtual biotechnology company pioneering the activation of gene expression with short activating RNA (saRNA).
Harnessing a proprietary algorithm, MiNA is developing a revolutionary class of therapeutics that activate key genes in major disease pathways. MiNA's ability to selectively activate master regulatory genes represents a new frontier in precision medicine.MTL-501 is a saRNA liver cancer therapeutic that activates the CEBPA gene. Intravenous injection of MTL-501 in a liver cancer rat model reduced tumour burden by 80% whilst increasing significantly serum albumin. In vitro work has indicated the dramatic potential of CEBPA saRNA as a universal anti-cancer therapeutic in non-small cell lung, prostate, pancreas, leukaemia, lymphoma and glioblastoma. MTL-301 is a Type 1 diabetes therapeutic. In vitro work demonstrated glucose responsive insulin secretion by both CD34+ adult stem cells and HepG2 cells.
Sphere Fluidics Limited is an innovative Life Sciences company which delivers miniaturised products, systems and collaboration services in field of single cell analysis.
Sphere’s core technology is in the field of high throughput Picodroplet generation and analysis and has significant patent portfolio that protects its core expertise. It enables ultra-high throughput analysis of single cells and generation of their genetic, transcriptomic and proteomic profiles in miniaturised (pl to nl) volumes.
Uniquely, as well as allowing single cell studies, the systems enable the study of different, large biomolecules that interact with or are secreted by those single cells. The latter application is very powerful as many human biotherapeutics, industrial enzymes (isolated mainly from micro-organisms) and around 15% of the Human Proteome are secreted, so cannot readily be analysed using conventional technology
Sphere Fluidics' technology enables diverse applications such as study of the mechanism of cancer cell resistance to chemotherapy, generation of new enzymes and identification of novel microbial strains.
Sphere Fluidics has established multiple commercial partnerships, received Venture Capital investment and with its founders the Company have received almost £10 million in science and business funding to date.
Sphere Fluidics LtdPrincipal Engineer
Dr Catherine Hunter
CrystecPharma applies the latest supercritical fluid (SCF) technologies to improve the design and performance of medicines. We provide crystal and particle engineering solutions to the pharmaceutical industry, contributing to human health by enabling new and more effective therapies.
Crystec SCF technologies can be applied to both small drug molecules and biomolecules.
Our services include crystal form screening and particle design, addressing issues of poor solubility and stability, improved delivery, and product enhancement in support of lifecycle management.
We are also engaged in in-house programmes to develop improved small and large molecule therapeutic products.
Our objectives this year at BioEurope are to identify new clients wishing to enhance the performance of their small and large moilecule therapeutics as well as identifying co-development partners, for supergeneric and new drugs.
Ms Eva Hurst
About Competitive Drug Development International Ltd.
CDDI is an international biotechnology and pharmaceutical consulting company, led by senior people who together have developed more than 20 products globally from discovery to market. CDDI can give support with a broad range of drug development activities across the three key disciplines of Clinical, Non-clinical and CMC.
Services include Virtual Asset Development (VAD), where CDDI provides a fully integrated development team directed by strong project leadership, Evidence Based Protocol Feasibility (ebf) for data-driven and rapid patient recruitment, and CMC services from API and formulation development of NCEs and NBEs, through to CMO management of GMP manufacturing.
Our working method is hands-on, not just consulting, which means, we don’t just advise you, but actively implement the strategies and plans that we formulate with you. For more information please visit www.cddi.co.